GlassScriptPhysician profile
Nicole M Held
NPI 1477085652
$3,496.31
in general payments reported to CMS, 2019-2025
12 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $480 · 2023: $530 · 2024: $427 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,642 · Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,642.16 |
| Food and Beverage | $1,261.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,722.07 | 2023-2025 | Cabometyx |
| Tempus Ai, INC | $278.01 | 2024-2025 | Xt Cdx |
| Abbvie INC. | $272.72 | 2021-2023 | |
| Beigene USA, INC. | $177.91 | 2022-2024 | Brukinsa |
| Astellas Pharma US INC | $159.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $153.07 | 2023-2025 | Calquence |
| Syndax Pharmaceuticals, INC. | $125.00 | 2025 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Incyte Corporation | $124.99 | 2023 | Jakafi |
| Genzyme Corporation | $124.54 | 2024 | |
| Lilly USA, LLC | $122.07 | 2024 | |
| Genmab U.S., INC. | $110.99 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Held listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.